The Dawn of a New Era in Metabolic Disease Management The announcement at the ADA meeting highlighted retatrutide’s remarkable efficacy,…
Read More
Eli Lilly’s Retatrutide Achieves Unprecedented Weight Loss in TRIUMPH-1 Trial, Signaling New Era in Obesity Pharmacotherapy
NEW ORLEANS, LOUISIANA – At the 86th Scientific Sessions of the American Diabetes Association (ADA) held in New Orleans, Louisiana,…
Read More
Retatrutide Eases Sleep Apnea and Knee Arthritis in New Phase 3 Data, Extending Lilly’s Obesity Lead Over Novo
Eli Lilly announced groundbreaking detailed Phase 3 results for its investigational triple agonist, retatrutide, at the American Diabetes Association’s (ADA)…
Read More
Scaling GLP-1 Obesity Trials Without Losing DXA Data
The explosive growth of global obesity trials, fueled by the success of GLP-1 receptor agonist therapies, presents a critical challenge:…
Read More
Beyond the silver bullet: Why precision medicine is the next frontier for the $1 trillion obesity market
The dramatic emergence of GLP-1 receptor agonists has undeniably revolutionized the landscape of obesity treatment, driving pharmaceutical giants like Eli…
Read More
Beyond the silver bullet: Why precision medicine is the next frontier for the $1 trillion obesity market
The dramatic rise of GLP-1 agonists, once hailed as a universal panacea for the global obesity epidemic, is increasingly being…
Read More
Tirzepatide Confirmed as Best-in-Class Obesity Therapy Following Landmark SURMOUNT-MAINTAIN Trial Results
Findings from the pivotal Phase III SURMOUNT-MAINTAIN trial, presented at the 33rd European Congress on Obesity (ECO) in Istanbul, Türkiye,…
Read More
Tirzepatide Shows Promising Adjunct Benefits in Type 1 Diabetes Management, Meta-Analysis Presented at European Congress on Obesity Suggests
The burgeoning field of GLP-1 receptor agonists, celebrated for their transformative impact on obesity and type 2 diabetes (T2D) management,…
Read More
Novel Combination Therapy CagriSema Demonstrates Promising Results in Obesity Management with Preserved Muscle Strength
On 12 May 2026, at the 33rd European Congress on Obesity (ECO) in Istanbul, Türkiye, groundbreaking findings from the Phase…
Read More
Beyond the silver bullet: Why precision medicine is the next frontier for the $1 trillion obesity market
The burgeoning global market for obesity treatments, propelled past the $1 trillion valuation by the meteoric rise of GLP-1 receptor…
Read More
